drugset / Trial / NCT03246321

PIPAC for Peritoneal Metastases of Colorectal Cancer

NCT03246321 ↗

Phase 2 Completed 20 enrolled Koen Rovers
NaSingle-groupOpen-labelTreatment

Summary

This is multicentre, open-label, single-arm phase II study that investigates the feasibility, safety, tolerability, preliminary efficacy, costs, and pharmacokinetics or repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC-OX) as a palliative monotherapy for patients with isolated unresectable colorectal peritoneal metastases.

Timeline

Start
2017-10-01
Primary completion
2019-10-01
Completion
2019-10-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxaliplatin Small molecule 92 mg/m2 Other
Background Leucovorin Small molecule 20 mg/m2 Intravenous
Background fluorouracil Small molecule 400 mg/m2 Intravenous